Skip to main content
Log in

Adaptive Design Practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013

  • Regulatory Science: Analytical Report
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Adaptive designs have generated great interest in the clinical trial community as a result of their versatility and efficiency. Recently, the Center for Devices and Radiological Health (CDRH) at the US Food and Drug Administration (FDA) surveyed all adaptive design applications submitted between 2007 and May 2013 for regulatory review. In this paper, we discuss the overall results and findings that emerged from an in-depth examination of the submissions. We summarize the current status of adaptive designs used in medical device studies. We also identify some of the lessons learned and common pitfalls that we encountered in our review of the designs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Food and Drug Administration. Draft guidance for industry and Food and Drug Administration staff: adaptive designs for medical device clinical studies. Rockville, MD: FDA, 2015.

    Google Scholar 

  2. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64:191–199.

    Article  Google Scholar 

  3. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556.

    Article  Google Scholar 

  4. Lan KKG, DeMets DL. Group sequential procedures: calendar versus information time. Stat Med. 1987;8:1191–1198.

    Article  Google Scholar 

  5. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics. 1995;51:1315–1324.

    Article  CAS  Google Scholar 

  6. Cui L, Hung HM, Wang S. Modification of sample size in group sequential clinical trials. Biometrics. 1999;55:853–857.

    Article  CAS  Google Scholar 

  7. Müller H, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics. 2001;57:886–891.

    Article  Google Scholar 

  8. Chen YHJ, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising. Stat Med. 2004;23:1023–1038.

    Article  Google Scholar 

  9. Gao P, Ware JH, Mehta C. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18:1184–1196.

    Article  Google Scholar 

  10. Berry SM, Carlin BP, Lee JJ, et al. Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL: CRC Press; 2011.

    Google Scholar 

  11. Campbell G. Similarities and differences of Bayesian designs and adaptive designs for medical devices: a regulatory view. Stat Biopharm Res. 2013;5:356–368.

    Article  Google Scholar 

  12. Morgan CC, Huyck S, Jenkins M, et al. Adaptive Design: Results of 2012 Survey on Perception and Use. Therapeutic Innovation & Regulatory Science. 2014;48:473–81.

    Article  Google Scholar 

  13. Elsäßer A, Regnstrom J, Vetter T, et al. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials. 2014;15:383.

    Article  Google Scholar 

  14. Lin M, Lee S, Zhen B, et al. CBER’s experience with adaptive design clinical trials. Therapeutic Innovation & Regulatory Science. 2015; September 16 online.

  15. Shih W. Sample size re-estimation—journey for a decade. Stat Med. 2001;20:515–518.

    Article  CAS  Google Scholar 

  16. Food and Drug Administration. Guidance for the use of bayesian statistics in medical device clinical trials. Rockville, MD: FDA, 2010.

    Google Scholar 

  17. Gelman A, Carlin J, Stern H, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis. Boca Raton, FL: CRC Press; 2014.

    Google Scholar 

  18. Pennello G, Thompson L. Experience with reviewing Bayesian medical device trials. J Biopharm Stat. 2008;18:81–115.

    Article  Google Scholar 

  19. Campbell G. Bayesian statistics in medical devices: innovation sparked by the FDA. J Biopharm Stat. 2011;21:871–887.

    Article  Google Scholar 

  20. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.

    Article  Google Scholar 

  21. Moher D, Hopewell S, Schulz F, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.

    Article  Google Scholar 

  22. Detry M, Lewis L, Broglio K, et al. Standards for the design, conduct, and evaluation of adaptive randomized clinical trials, http://www.pcori.org/assets/Standards-for-the-Design-Conduct-and-Evaluation-of-Adaptive-Randomized-Clinical-Trials.pdf. Published 2012. Accessed March 15, 2012.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Xiting Yang PhD.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, X., Thompson, L., Chu, J. et al. Adaptive Design Practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013. Ther Innov Regul Sci 50, 710–717 (2016). https://doi.org/10.1177/2168479016656027

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479016656027

Keywords

Navigation